Agendia, Inc : Landmark Long-Term Data from EORTC s MINDACT Study Published in The Lancet Oncology finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(1)
Results support use of Agendia s genomic tests to better tailor pre-operative treatment and timing for surgery
Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint and BluePrint
, and underpin both assays pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at the 38
th Annual Miami Breast Cancer Conference.
The poster, entitled
Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients,
outlines the first age-based analyses of MammaPrint and BluePrint assays in the pre-operative setting. As expected, the data show that pCR rates varied according to molecular subtype, with MammaPrint and BluePrint accurately predicting pCR in patients of all subtypes, regard
(1) Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted in an oral presentation by Laura van t Veer, Ph.D., Co-founder and Chief Research Officer, at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). These data highlight the ability of MammaPrint
, Agendia s 70-gene breast cancer recurrence assay, to further stratify patients with clinically low risk breast cancer which could impact physician-patient discussions and treatment planning.
MINDACT (?M?icroarray ?I?n ?N?ode-Negative and 1-3 node-positive ?D?isease may ?A?void Chemo?T?herapy), the Phase 3, prospective, randomized clinical trial supported by the European Organization for Research and Treatment of Cancer (EORTC), was designed to determine whether MammaPrint could be used to safely de-escalate patients with early stage breast cancer from chemotherapy without compromising their outcomes. Updated o
Posted on 8875
Agendia, Inc., a world leader in precision oncology for breast cancer, presented data from the FOCUS trial that show the clinical utility of MammaPrint
The poster,
The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients, outlines data from the FOCUS trial, a population-based cohort of over 2,000 people that included all consecutive breast cancer patients over 65 years old diagnosed between 1997 and 2004 in the Comprehensive Cancer Center region West, the Netherlands. The purpose of the study was to assess the stratification of breast cancers by MammaPrint in women over 70 years of age.
Treating older breast cancer patients can be challenging, as they generally have more indolent tumors and a higher likelihood of developing additional conditions that negatively affect their health than younger patients. Current treatment guidelines recommend therapy
Agendia, Inc.: Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint
Clinical utility of molecular subtyping and risk of recurrence profiling highlighted in largest-ever data set evaluating genomic testing in neoadjuvant setting
First look at full 5-year NBRST trial outcome and survival data illustrate genomic diversity within all clinical subtypes of breast cancer Agendia, Inc., a world leader in precision oncology for breast cancer, announced new 5-year data from the NBRST trial that will be presented in a poster spotlight discussion Thursday, December 10, 2020 from 3:30pm-4:45pm CST at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).
The poster, entitled